Literature DB >> 22426377

The burden of hospitalizations for anus and penis neoplasm in Spain (1997-2008).

Ruth Gil-Prieto1, Pablo Viguera Ester, Alejandro Álvaro-Meca, María San Martín Rodríguez, Ángel Gil De Miguel.   

Abstract

An epidemiological retrospective study has been performed to assess the burden of hospitalization by anus and penis neoplasm in the general population in Spain. All hospital discharges and deaths related to anal malign neoplasm and penile malign neoplasm from 1997 to 2008 in Spain were obtained. A total of 19,608 hospital admissions were recorded during the study period: 11,965 were related to anal malign neoplasm (4,992 in women and 6,973 in men) and 7,643 to penis malignant neoplasm. This corresponds to a hospitalization rate of 1.97 (CI 95%: 1.91-2.02) hospitalizations per 100,000 women/ year, 2.84 (CI 95%: 2.77-2.91) hospitalizations per 100,000 men/ year and 3.11 (CI 95%: 3.04- 3.18) hospitalizations per 100,000 men/ year, respectively during the study period.   The hospitalization rate increased significantly during the study period in all locations. It also increased significantly with age for all locations. Hospitalization and mortality rates in men were 50% higher than in women A total of 530 deaths related to penis malignant neoplasm and 738 deaths related to anus malignant neoplasm in men and 488 in women were reported during the 12-y study period. Although a decrease in smoking prevalence has led to a decrease in the incidence of cancers in the last decade, the hospitalizations due to anal and penile malign neoplasm have not declined in our study. This might be attributed to a high prevalence of HPV infection in these particular genital malign neoplasms.

Entities:  

Mesh:

Year:  2012        PMID: 22426377     DOI: 10.4161/hv.18388

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  6 in total

1.  Hospitalizations associated with malignant neoplasia and in situ carcinoma in the anus and penis in men and women during a 5-year period (2009-2013) in Spain: An epidemiological study.

Authors:  Noelia López; Ángel Gil-de-Miguel; Raquel Pascual-García; Ruth Gil-Prieto
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

2.  The natural history of genital human papillomavirus among HIV-negative men having sex with men and men having sex with women.

Authors:  Alan G Nyitray; Mihyun Chang; Luisa L Villa; Roberto J Carvalho da Silva; Maria Luiza Baggio; Martha Abrahamsen; Mary Papenfuss; Manuel Quiterio; Jorge Salmerón; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  J Infect Dis       Date:  2015-02-03       Impact factor: 5.226

3.  Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.

Authors:  Jesús De La Fuente; Juan José Hernandez Aguado; María San Martín; Paula Ramirez Boix; Sergio Cedillo Gómez; Noelia López
Journal:  Hum Vaccin Immunother       Date:  2019-02-20       Impact factor: 3.452

4.  Evaluation of the Burden of HPV-Related Hospitalizations as a Useful Tool to Increase Awareness: 2007-2017 Data from the Sicilian Hospital Discharge Records.

Authors:  Vincenzo Restivo; Claudio Costantino; Livia Amato; Stefania Candiloro; Alessandra Casuccio; Marianna Maranto; Alessandro Marrella; Sara Palmeri; Stefano Pizzo; Francesco Vitale; Emanuele Amodio
Journal:  Vaccines (Basel)       Date:  2020-01-26

5.  Hospitalization for diseases attributable to human papillomavirus in the Veneto Region (North-East Italy).

Authors:  Vincenzo Baldo; Silvia Cocchio; Alessandra Buja; Tatjana Baldovin; Patrizia Furlan; Chiara Bertoncello; Mario Saia
Journal:  BMC Infect Dis       Date:  2013-10-05       Impact factor: 3.090

6.  Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine.

Authors:  Noelia López; Aureli Torné; Agustín Franco; María San-Martin; Elisabet Viayna; Carmen Barrull; Nuria Perulero
Journal:  Infect Agent Cancer       Date:  2018-05-02       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.